Godmanchester PE29 2XG
Situated on a new industrial park next to A14 with other high tech users including CDT, pharmaceutical companies and healthcare multinationals (Smith and Nephew). Cambridge 15 miles via upgraded A14.
Offered as a single unit of 10,000 sq ft. or as one or two separate units of 5,000 sq ft.
Units can be separated into two separate 5,000 sq ft units.
Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics’ experienced team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
Researchers at the Cira Foundation (Kyoto, Japan) have published an informative study** that highlights how defined culture conditions using Amsbio StemFit™ Basic03 medium coupled with a supportive matrix (iMatrix-511) contribute to controlling hiPSC behaviour and differentiation efficiency.
The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in Cancer Stem Cell Biology to play a pivotal role in advancing our cutting-edge cancer research. The position will be based in newly-refurbished laboratory and office space at our Sutton campus within the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels.
The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in In Vivo Cancer Modelling to play a pivotal role in advancing our cutting-edge cancer research. The position is based at the newly established Centre for In Vivo Modelling (CIVM), part of the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels.
Key Requirements
LONDON, UK – January 20, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO).
Researchers' expectations of antibodies are changing—from "whether they can be used" to "whether they are stable enough, easy to engineer, and truly meet research needs."